<DOC>
	<DOCNO>NCT03103919</DOCNO>
	<brief_summary>Evaluate benefit Kinesia-360™ wearable technology addition standard clinical practice improve Parkinson´s disease motor symptom , Neupro dose regimen adherence Neupro compare standard clinical practice .</brief_summary>
	<brief_title>Study Evaluate Impact Using Wearable Devices Addition Standard Clinical Practice Parkinson´s Subject Symptoms Management</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject newly prescribe Neupro expect commence Neupro treatment . Historical Neupro treatment permit Informed Consent form ( ICF ) sign date subject , studyrelated procedure Subject consider reliable capable adhere protocol , visit schedule , completion diary , use Kinesia device accord judgment Investigator Male female subject , &gt; =18 year age time Screening Visit Subject Parkinson 's disease , define cardinal sign , bradykinesia , plus presence least 1 follow : tremor rest , rigidity impairment postural reflex , without know suspected cause Secondary Parkinsonism Subject experience motor symptom associate Parkinson 's disease sufficiently control current therapy . The average triplicate rest tremor score triplicate finger tap score KinesiaONE™ ( 6 score total ) must &gt; 1.0 Subject currently participate study investigational medicinal product investigational device Subject medical , neurological psychiatric condition , opinion Investigator , could jeopardize would compromise subject 's ability participate study Subject Deep Brain Stimulation ( DBS ) device implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Parkinson´s Disease</keyword>
	<keyword>Kinesia-360™</keyword>
	<keyword>Kinesia-ONE™</keyword>
	<keyword>Biosensor</keyword>
</DOC>